Compare CALM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALM | NRIX |
|---|---|---|
| Founded | 1957 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 1996 | 2020 |
| Metric | CALM | NRIX |
|---|---|---|
| Price | $61.19 | $26.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $68.33 | $34.50 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 09-30-2026 | 10-12-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 3.26 |
| Revenue | ★ $2,911,632,000.00 | $76,987,000.00 |
| Revenue This Year | N/A | $786.93 |
| Revenue Next Year | $12.37 | N/A |
| P/E Ratio | ★ N/A | $8.32 |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $60.13 | $11.67 |
| 52 Week High | $95.25 | $28.23 |
| Indicator | CALM | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 67.26 |
| Support Level | $61.01 | $24.61 |
| Resistance Level | $80.00 | $28.23 |
| Average True Range (ATR) | 1.88 | 1.31 |
| MACD | 0.36 | 0.40 |
| Stochastic Oscillator | 17.40 | 98.89 |
Cal-Maine Foods Inc is an egg company in the U.S. Its shell egg portfolio includes conventional, specialty, cage-free, nutritionally enhanced, organic, brown, pasture-raised, and free-range eggs. The Company operates through the Conventional Shell Eggs, Specialty Shell Eggs and Prepared Foods segments, with Conventional Shell Eggs generating maximum revenue. The Conventional Shell Eggs segment consists mainly of the production, grading, packaging, marketing and distribution of conventional shell eggs, including Sunups and Sunny Meadow. The Company sells its products to grocery store chains, club stores, independent supermarkets, and foodservice distributors serving restaurants, convenience stores, healthcare and education facilities, and hotels throughout the U.S.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.